Industry Sessions Program
Discover the industry symposia taking place at WCN on Sunday March 29, Monday March 30 and Tuesday March 31. These sessions, delivering the latest advancements in global kidney care, are scheduled at different times throughout the days.
Select industry symposia will be livestreamed with open-access – see more in the description below. All industry symposia will be available on-demand on the ISN Academy after the congress.
Lunch will be provided to attendees of lunch symposia. Selected breakfast and afternoon symposia will provide light refreshments.
- Bringing innovative CKD treatments to patients without delay: Barriers and Solutions
Organized by AstraZeneca
8:10 – 9:10 | Room 301+302 | Slot 5
Pediatric Nephrotic Syndrome
Organized by Chugai Pharmaceutical Co.,Ltd.
08:10 – 09:10 | Room 303 | Slot 2
- Comprehensive management of Chronic Kidney Disease : Insights from Japan
Organized by Kowa Co., Ltd.
08:10 – 09:10 | Room 315 | Slot 1
- CKD-MBD
Organized by Kyowa Kirin
08:10 – 09:10 | Room 503 | Slot 4
- Uric Acid and Kidney Disease
Organized by Mochida Pharmaceutical Co.,Ltd./Fujiyakuhin Co.Ltd.
08:10 – 09:10 | Room 304 | Slot 3
- Targeting Pathogenic IgA in IgA Nephropathy
The scientific content of this symposium has been independently developed by ISN. Supported by Takeda
08:10 – 09:10 | Room 501+502 | Slot 6
- Addressing unmet needs in immune mediated kidney diseases, one antibody at a time
Organized by Biogen
12:50 – 13:50 | Room 303 | Slot 14
- Hypertension Management Aimed at Achieving Target Blood Pressure : The Clinical Utility of Mineralocorticoid Receptor Antagonists
Organized by Daiichi-Sankyo
12:50 – 13:50 | Room 501+502 | Slot 18
- Every note matters: collective action to change the tune of IgA nephropathy
Organized by Novartis Pharma AG
12:50 – 13:50 | Room 503 | Slot 16
- Exploring the Role of APRIL in IgA Nephropathy: Pathogenesis to Progression
- Organized by Otsuka
12:50 – 13:50 | Rooma 301+302 | Slot 17
- Shared Decision-Making (SDM) in Dialysis: Turning Conversations into Care
- Organized by Vantive
- 12:50 – 13:50 | Room 304 | Slot 15
- Hyperkalemia in CKD and Heart Failure
Organized by Zeria Pharmaceutical Co., Ltd.
12:50 – 13:50 | Room 315 | Slot 13
- The Complement Connection: Rethinking Disease Progression in IgA Nephropathy
- Organized by Alexion Pharmaceuticals Inc.
- 17:00 – 18:00 | Room 304 | Slot 27
- Conquering Kidney Disease: Strategies, Evidence, and Innovations Worldwide
Organized by AstraZeneca K.K.
17:00 – 18:00 | Room 501+502 | Slot 30
- Evolving Landscape of IgA Nephropathy in 2026 and Beyond
Organized by Chugai Pharmaceutical Co.,Ltd.
17:00 – 18:00 | Room 303 | Slot 26
- Chronic Kidney Disease in Children: Challenges of Diagnosis, Screening, and Management
Organized by Boehringer Ingelheim GmbH
8:10 – 9:10 | Room 304 | Slot 33
- Complement-Mediated Kidney Disease: From Mechanisms to Therapies
Organized by eleva GmbH
8:10 – 9:10 | Room 315 | Slot 31
- GLP-1RAs in Kidney Disease: Mechanisms, Applications in Clinical Practice and the Future
- The scientific content of this symposium has been independently developed by ISN. Supported by Novo Nordisk
8:10 – 9:10 | Room 301+302 | Slot 35
- New horizons in C3G and primary IC-MPGN: navigating the future of patient care
Organized by Swedish Orphan Biovitrum AB
8:10 – 9:10 | Room 503 | Slot 34
- Emerging Therapeutic Approaches in IgA Nephropathy: Innovations in B-Cell Modulation and Dual BAFF/APRIL Inhibition
Organized by Vera Therapeutics
8:10 – 9:10 | Room 501+502 | Slot 36
- Combination with Confidence: Finerenone for Kidney and Heart Protection
Organized by Bayer AG
12:50 – 13:50 | Room 501+502 | Slot 48
- CKD in focus: Enhancing risk detection and management approaches
Organized by Boehringer Ingelheim GmbH
12:50 – 13:50 | Room 304 | Slot 45
- The Evolving IgAN Treatment Paradigm- Why target the gut?
Organized by Calliditas Therapeutics
12:50 – 13:50 | Room 303 | Slot 44
- KDIGO presents the Importance of Targeting IgAN Disease Drivers: Real-World Practice Using Case-based Illustrations
Organized by KDIGO
12:50 – 13:50 | Room 301+302 | Slot 47
- A New Era for Patients with C3G: Redefining Standard of Care
Organized by Novartis Pharma AG
12:50 – 13:50 | Room 503 | Slot 46
- Reimagining Anemia Management in CKD: Evolution with HIF-PHIs
Organized by Zydus LifeSciences
12:50 – 13:50 | Room 315 | Slot 43
- The significance of potassium management in CKD treatment
Organized by AstraZeneca K.K.
17:00 – 18:00 | Room 303 | Slot 56
- Beyond the kidneys: the importance of early intervention and managing cardiovascular risk in patients with CKD
Organized by Boehringer Ingelheim GmbH
17:00 – 18:00 | Room 301+302 | Slot 59
- Comprehensive Management of Fabry Disease: Latest Evidence from Korea and Japan
Organized by Sanofi K. K.
17:00 – 18:00 | Room 315 | Slot 55
- Rethinking IgA Nephropathy Through Mucosal Immunity: Integrating Tonsillar and Intestinal Perspectives
Organized by Viatris Pharmaceuticals Japan G.K. Medical Affairs
17:00 – 18:00 | Room 503 | Slot 58
- Revisiting MR-Mediated Electrolyte Imbalance at the Tissue Level : Implications for MR Blockade and JSH2025 Guidelines
Organized by Daiichi-Sankyo
8:00 – 9:00 | Room 303 | Slot 61
Spotlight Stage
Located in exhibition hall the Spotlight Stages features short, dynamic and interactive presentations from industry, ISN programs, ISN social media team and more.
Sunday, March 29, 2026
- Atypical hemolytic uremic syndrome (aHUS) in focus
- Organized by Alexion Pharmaceuticals Inc.
- 11:00 – 12:00 | Spotlight Stage 1 | Slots 10+12
- Integrating Drug Action Profiles and Innovative Trial Design in Complement-Mediated Inflammatory Kidney Diseases
- Organized by eleva GmbH
- 14:10 – 14:40 | Spotlight Stage 1 | Slot 20
Monday, March 30, 2026
- From evidence to everyday practice: key aspects in the management of patients with non-diabetic CKD
- Organized by BioKindle
- 14:10 – 14:40 | Spotlight Stage 1
Sunday, March 29, 2026
- Translating intention into action: Growing and sustaining home dialysis program
- Organized by Vantive
- 11:35 – 12:05 | Spotlight Stage 2 | Slot 9
- Treating CV risk in CKD: from identification to intervention
- Organized by Boehringer Ingelheim GmbH
- 14:30 – 15:00 | Spotlight Stage 2 | Slot 19
- Utilizing Remote Patient Management in PD Treatment: Sharesource & MyPD Enables Team-Based Care and Healthcare Collaboration
- Organized by Vantive
- 15:15 – 15:45 | Spotlight Stage 2 | Slot 21
Monday, March 30, 2026
- Empowering Nurses is Key For Home Dialysis Expansion
- Organized by Vantive
- 11:00 – 11:30 | Spotlight Stage 2 | Slot 39
- Guided by evidence: a unified approach to CKD, diabetes and HF management
- Organized by Bayer AG
- 15:15 – 15:45 | Spotlight Stage 2 | Slot 51
Advertisment
